Larson Financial Group
RXRX icon

Larson Financial Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Larson Financial Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.06K Buy
+500
New +$1.7K ﹤0.01% 3218
2026
Q2 		– Sell
-501
Closed -$1.54K – 3899
2026
Q1 		$1.54K Hold
501
– – ﹤0.01% 3034
2025
Q4 		$2.05K Buy
501
+496
+9,920% +$2.46K ﹤0.01% 2779
2025
Q3 		$24 Buy
+5
New +$26 ﹤0.01% 3388
2024
Q4 		– Sell
-207
Closed -$1.36K – 2885
2024
Q3 		$1.36K Sell
207
-101
-33% -$724 ﹤0.01% 1922
2024
Q2 		$2.31K Buy
308
+199
+183% +$1.74K ﹤0.01% 1575
2024
Q1 		$1.09K Buy
+109
New +$1.21K ﹤0.01% 1438

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Larson Financial Group's RXRX Position: Q3 2026 in Review

Larson Financial Group opened a new position in Recursion Pharmaceuticals (RXRX) in Q3 2026: 500 shares worth $2.06K. The stake represents ﹤0.01% of the portfolio and ranks #3218 among its holdings. This is a return to the name: Larson Financial Group previously reported a position in RXRX as recently as Q1 2026.

Larson Financial Group first reported a position in RXRX in Q1 2024 and has held it in 7 quarters since. The position peaked at $2.31K in Q2 2024. 150 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Larson Financial Group held 500 shares of Recursion Pharmaceuticals worth $2.06K as of Q3 2026.
  • Recursion Pharmaceuticals was a new Larson Financial Group position in Q3 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #3218 holding.
  • Larson Financial Group first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • Larson Financial Group's Recursion Pharmaceuticals position peaked at $2.31K in Q2 2024.
  • 150 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.